Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer

Clinical trial NCT06900595 · RECRUITING

Trial details

NCT number: NCT06900595
Sponsor: National Cancer Institute (NCI)
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Locally Advanced Adrenal Cortical Carcinoma Metastatic Adrenal Cortical Carcinoma Recurrent Adrenal Cortical Carcinoma Stage III Adrenal Cortical Carcinoma AJCC v8 Stage IV Adrenal Cortical Carcinoma AJCC v8 Unresectable Adrenal Cortical Carcinoma

Start date: 2026-02-22
Primary completion: 2029-06-02
Enrollment: 48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.